Radiolabeled Herceptin to Increase Treatment Efficacy in Breast Cancer Patients with Low Tumor HER-2/neu Expression
Abstract
The primary objective of the proposal is to evaluate the efficacy and feasibility of using radio labeled Herceptin antibody to target rapidly accessible breast carcinoma cells or micrometastases. By using Herceptin to specifically deliver radiation we anticipate that the efficacy of Herceptin will be extended to include breast cancer cells that are not high-HER-2/neu antigen expressors. This hypothesis will be tested using the spheroid model to simulate rapidly accessible micrometastases. An alpha-particle emitting radionuclide will be used to enhance tumor cell kill. Completion of tasks 1 and 2 was reported in the previous annual report. Cell kill experiments using Herceptin labeled with an alpha-particle emitter have been carried out; dose-response studies have been completed(task 3). Examination of alpha-emitter and radio sensitizer combinations has begun (task 4: months 21-24) and preliminary work on an animal model to investigate radio labeled Herceptin targeting of HER2/neu positive disease has been completed (task 5).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2002
- Accession Number
- ADA408089
Entities
People
- George Sgouros
Organizations
- Memorial Sloan Kettering Cancer Center